中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2013年
33期
6-8
,共3页
布拉氏酵母菌%小儿%急性腹泻%微生态制剂
佈拉氏酵母菌%小兒%急性腹瀉%微生態製劑
포랍씨효모균%소인%급성복사%미생태제제
Saccharomyces boulardii%Children%Acute diarrhea%Probiotics
目的：探讨布拉氏酵母菌治疗小儿急性腹泻的临床疗效。方法对本院收治2012年5月~10月的90例小儿急性腹泻患儿的临床资料进行回顾性分析,根据用药方法不同分为观察组和对照组,对照组患儿给予益生菌、补锌剂、蒙脱石散剂口服及补液等常规治疗,观察组在对照组治疗基础上加用布拉氏酵母菌散剂治疗。对两组的临床疗效、止泻时间情况进行对比分析。结果观察组有效率明显高于对照组(P<0.01)；两组患儿在治疗后3d平均大便次数均较治疗前明显降低,且观察组改善更加明显(P<0.05)；治疗后7 d,两组患儿平均大便次数比较,差异无统计学意义(P>0.05)；观察组平均止泻时间明显少于对照组(P<0.05)。结论使用布拉氏酵母菌能有效提高临床疗效,减少大便次数,缩短腹泻持续时间。
目的：探討佈拉氏酵母菌治療小兒急性腹瀉的臨床療效。方法對本院收治2012年5月~10月的90例小兒急性腹瀉患兒的臨床資料進行迴顧性分析,根據用藥方法不同分為觀察組和對照組,對照組患兒給予益生菌、補鋅劑、矇脫石散劑口服及補液等常規治療,觀察組在對照組治療基礎上加用佈拉氏酵母菌散劑治療。對兩組的臨床療效、止瀉時間情況進行對比分析。結果觀察組有效率明顯高于對照組(P<0.01)；兩組患兒在治療後3d平均大便次數均較治療前明顯降低,且觀察組改善更加明顯(P<0.05)；治療後7 d,兩組患兒平均大便次數比較,差異無統計學意義(P>0.05)；觀察組平均止瀉時間明顯少于對照組(P<0.05)。結論使用佈拉氏酵母菌能有效提高臨床療效,減少大便次數,縮短腹瀉持續時間。
목적：탐토포랍씨효모균치료소인급성복사적림상료효。방법대본원수치2012년5월~10월적90례소인급성복사환인적림상자료진행회고성분석,근거용약방법불동분위관찰조화대조조,대조조환인급여익생균、보자제、몽탈석산제구복급보액등상규치료,관찰조재대조조치료기출상가용포랍씨효모균산제치료。대량조적림상료효、지사시간정황진행대비분석。결과관찰조유효솔명현고우대조조(P<0.01)；량조환인재치료후3d평균대편차수균교치료전명현강저,차관찰조개선경가명현(P<0.05)；치료후7 d,량조환인평균대편차수비교,차이무통계학의의(P>0.05)；관찰조평균지사시간명현소우대조조(P<0.05)。결론사용포랍씨효모균능유효제고림상료효,감소대편차수,축단복사지속시간。
Objective To evaluate the efficacy of the probiotic yeast saccharomyces boulardiiin treatment of children with acute diarrhea.Methods In a period of five months(from March 2012 to Octorber 2012), 90 hospitalized children suffering from acute diarrhea,aged 6 months to 5 years,were included in a randomized placebo-controlled trial evaluating the efficacy of saccharomyces boulardii administered full period in hospital,with 45 children in the controlled group receiving conventional treatment(ORS,zinc supplementation, oral montmorillonite, antibiotics if necessary), other 45 children in the saccharomyces boulardii group receiving saccharomyces boulardii plus conventionab therapies.Results The efficacy in the saccharomyces boulardii in group statistically significantly higher than controlled group.On the 4th day, the efficacy in the patients in the saccharomyces boulardii group passed the efficacy in the controlled group.On the 7th day, the efficacy the patients in the saccharomyces boulardii group passed the efficacy in controlled group.A statistically sificant difference was observed in the number of stools on the 4th and 7th day favouring the subgroup that received early treatment. Conclusion Saccharomyces boulardii is able to raise clinical efficiency, and it reduced the duration of diarrhea, accelerated recovery and reduced the risk of prolonged diarrhea.
